Global Radiation Oncology Market Report 2023: Demand for Advanced Cancer Treatment Options Fuels Growth
June 06, 2023 05:28 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global radiation...
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 25, 2023 17:00 ET
|
PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023 07:30 ET
|
PDS Biotechnology Corporation
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE...
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients
April 27, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
April 18, 2023 09:00 ET
|
invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
April 03, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
March 30, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
March 29, 2023 07:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted...
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
March 28, 2023 07:30 ET
|
PDS Biotechnology Corporation
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor...
The Worldwide Proton Therapy Industry is Expected to Reach $963.6 Million by 2028
January 12, 2023 04:43 ET
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head &...